High levels were reported in the active plasma fraction of patients with recurrent FSGS compared to controls [33], and treatment of mice with recurrent doses of CLCF1-induced FSGS-like lesions [34]. The gene discussed is CLCF1; the disease is focal segmental glomerulosclerosis.